<DOC>
	<DOC>NCT01717404</DOC>
	<brief_summary>To understand if Mexiletine will restores normal colonic motility in a patient with irritable bowel syndrome - constipation (IBS-C) and a genetic mutation in SCN5A.</brief_summary>
	<brief_title>Effects of Mexiletine on Colonic Transit in a Patient With Irritable Bowel Syndrome - Constipation (IBS-C)</brief_title>
	<detailed_description>To understand if Mexiletine will restore normal colonic motility in a patient with a missense mutation in SCN5A, which encodes a voltage-sensitive sodium channel NaV1.5 as it is known to rescue certain expression defects of NaV1.5 in vitro.</detailed_description>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Mexiletine</mesh_term>
	<criteria>Established IBS diagnosis with a known A997T mutation in NaV1.5T Normal 48hour baseline transit study Current use of mexiletine Inability to stay in Rochester for 9 days for testing Known allergy to mexiletine Inability to complete daily diary Taking a medication known to affect myotonia, had a coexisting neuromuscular disease, or had another serious medical illness including second or thirddegree heart block, atrial flutter, atrial fibrillation, ventricular arrhythmia, history of cardiac arrhythmia requiring medication, congestive heart failure, symptomatic cardiomyopathy, or symptomatic coronary artery disease Inability to withdraw medications known to interact with mexiletine. Patient is currently not on any of these medications</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>IBS</keyword>
</DOC>